2 december 2017: klik op de titel:
Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor may now enroll in a Phase 1b/2a clinical trial testing a triple immunotherapy combination for the cancer.
Inovio Pharmaceuticals is leading the study to evaluate its T-cell activating therapies INO-5401 and INO-9012 in combination with cemiplimab, a PD-1 inhibitor developed by Regeneron Pharmaceuticals.
INO-5401 is...